Join to access to all OVN content. Join for Free

Results for 'product labeling'

...
OVN Avatar Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 9th • 5 mins read

...
Partner Avatar Tom Caravela
Mastering the First Impression

Jan 29th • 2 mins read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 17th • 2 mins read

...
Partner Avatar Tom Caravela
Resume Writing and Editing Tips for Pharma Professionals

Aug 8th • 1 min read

...
Partner Avatar Bridget Rasmusson
6 Tips to Ace Your Next MSL Interview!

Sep 28th • 1 min read

...
Partner Avatar Bridget Rasmusson
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Oct 12th • 1 min read

...
Partner Avatar Tom Caravela
Combatting the “Summer Slow Down"​ – MSL Job Search Tips for Slower Months

Jun 23rd • 2 mins read

...
Partner Avatar Tom Caravela
7 High-Cost Interview Mistakes that are Easy to Avoid

Jul 28th • 1 min read

...
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

Apr 5th • 1 min read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
Partner Avatar iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 3rd • 1 min read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins read

...
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7th • 12 mins read

...
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 8th • 4 mins read

...
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons

Sep 14th • 4 mins read

...
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20th • 12 mins read

...
OVN Avatar Jorge J. García, Luis E. Raez, Daniel Rosas
A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Aug 3rd • 10 mins read

...
OVN Avatar Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

Sep 6th • 20 mins read

...
OVN Avatar Peter N Morcos, Junyi Li, Iraj Hosseini, Chi‐Chung Li
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

Nov 18th • 15 mins read

...
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Aug 16th • 8 mins read